chevron_leftBack
As of 13 June 2026, Oncocross Co., Ltd. has a market cap of $72.5M USD, ranking #27850 globally and #1445 in South Korea.
It ranks #2512 in the Healthcare sector, and #902 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$72.5MUSD
110.25B KRW
Enterprise Value
$60.4MUSD
92.18B KRW
Revenue (TTM)
$243.59KUSD
370.46M KRW
EBITDA (TTM)
-$5.25MUSD
-8.02B KRW
Net Income (TTM)
-$5.87MUSD
-8.93B KRW
PS Ratio
297.6
PB Ratio
8.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
Founded
2015
Website
oncocross.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -6% | 2.8% | 34% | -4.4% | 9.8% | -29% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
382150
주식회사 온코크로스
ISIN: KR7382150001
Shares Out.:
Shares Outstanding:
12.196M1
Shares Float:
8.604M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
8,500 KRW |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Oncocross Co., Ltd.
Oncocross Co., Ltd. develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e for Inhibition of cancer metastasis; OC211, a Pan-KRAS Inhibitor; OC221, an immuno-oncology combination; OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 to treat atopic dermatitis. The company is also developing OJP3101 for metabolic disease; OJP3101 for Cardiovascular Disease; ODP9401 for metabolic disease; and ODP2201, ODP2301, and ODP2401 to treat oncology-related diseases. It has a collaboration agreement with various pharmaceutical companies, research institutes, and bio-techs. The company was founded in 2015 and is based in Seoul, South Korea.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
KRX: 0126Z0
|
$9.15B
13K%
13.91T KRW
|
-
|
|
KRX: 000250
|
$6.77B
9K%
10.3T KRW
|
1958.1
|
|
KRX: 326030
|
$5.24B
7K%
7.97T KRW
|
29.9
|
|
KRX: 298380
|
$4.96B
7K%
7.55T KRW
|
-
|
|
KRX: 000100
|
$4.55B
6K%
6.92T KRW
|
35.9
|
|
KRX: 141080
|
$4.44B
6K%
6.76T KRW
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
1M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
755K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
497K%
|
97.4
|
|
SIX: RO
|
$321.52B
443K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
398K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
379K%
218.9B CHF
|
20.5
|
chevron_leftBack